title: [Effects of protocol HX-97 on mobilization, collection and hematopoietic reconstitution of peripheral blood stem cells transplantation].
abstract: In order to enhance the effects of peripheral blood stem cell mobilization, collection and hematopoietic reconstitution, we observed and evaluated the effects of Protocol HX-97 on 22 patients who received allogeneic or autologous peripheral blood stem cell transplants from April 1997 to June 1999. rhG-CSF was used for mobilization at a dose of 300 micrograms/day for 6 days; the sixth dose was given an hour and a half before leukapheresis. High dose chemotherapy and rhG-CSF were given for autologous peripheral blood stem cell mobilization; the chemotherapy should be intensive enough to reduce the patients' peripheral WBC to less than 1.0 x 10(9)/L, and the beginning of using rhG-CSF should be just at the time of WBC's rising from the nadir. rhGM-CSF and rhG-CSF were given sequentially for hematopoietic reconstitution after transplantation. The results showed that leukaphereses were successfully performed for peripheral blood stem cell collection. Sixteen cases needed apheresis only once, and 6 cases needed it twice. The harvests were 2.5-10.7 x 10(8)/kg MNC, 2.5-20.0 x 10(6)/kg CD34+ cells (including 1.8-7.5 x 10(6)/kg CD34+CD33-, 0.7-12.5 x 10(6)/kg CD34+CD33+), and 3.5-6.3 x 10(5)/kg CFU-GM. Hematopoietic function recovered to > 0.5 x 10(9)/L of neutrophil count in allo-PBSCT at 14-20 days and in auto-PBSCT at 12-20 days, and to > 20 x 10(9)/L of platelet count in allo-PBSCT and in auto-PBSCT at 16-34 days and 16-28 days, respectively. At day +30 post-transplantation, chromosome analysis and DNA finger print assessment of bone marrow cells indicated that the patients' hematopoietic function had been reconstituted. This study suggests that Protocol HX-97 is an effective approach to mobilization of peripheral blood stem cell transplantation, and it is relatively cost-effective.
authors.affiliation: Department of Hematology, First Affiliated Hospital, WCUMS, Chengdu 610041.
authors.forename: T
authors.initials: T
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Jia
authors.forename: Z
authors.initials: Z
authors.lastname: Lu
authors.forename: L
authors.initials: L
authors.lastname: Qin
authors.forename: C
authors.initials: C
authors.lastname: Xu
authors.forename: J
authors.initials: J
authors.lastname: Wu
authors.forename: C
authors.initials: C
authors.lastname: Deng
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor